Mutual combination of CD19 and KITmut can deliver a more definite risk stratification profile for t(8;21) AML, thereby guiding an individually risk‐adapted curative treatment, such as allo‐SCT. This evidence concerns the gene CD19 and acute myeloid leukemia.